Hemostat Dosage & Drug Information

Concise Prescribing Info Full Prescribing Info Contents Action Indications/Uses Dosage/Direction for Use Contraindications Special Precautions Use In Pregnancy & Lactation Side Effects Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Concise Prescribing Info

Contents

Tranexamic acid

Indications/Uses

Short-term use for haemorrhage in increased fibrinolysis or fibrinogenolysis. Hereditary angioneurotic oedema.

Click to view Hemostat detailed prescribing information

Dosage/Direction for Use

Cap 15-25 mg/kg bd-tds. Menorrhagia 1 g tds for up to 4 days. Max: 4 g daily. Hereditary angioedema 1-1.5 g bd-tds. Slow IV Local fibrinolysis 0.5-1.3 g tds.

Click to view Hemostat detailed prescribing information

Administration

May be taken with or without food.

Contraindications

History of thromboembolic disease & severe renal impairment.

Click to view Hemostat detailed prescribing information

Special Precautions

Patients w/ irregular menstrual bleeding & w/ a high risk for thrombosis. Pregnancy & lactation. Childn <15 yr w/ menorrhagia. Elderly w/ renal failure.

Click to view Hemostat detailed prescribing information

Use In Pregnancy & Lactation

Click to view Hemostat detailed prescribing information

Adverse Reactions

GI discomfort eg nausea, vomiting, diarrhoea.

Storage

View Hemostat storage conditions for details to ensure optimal shelf-life.

Action

View Hemostat mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Haemostatics

ATC Classification

B02AA02 - tranexamic acid ; Belongs to the class of amino acid antifibrinolytics. Used in the treatment of hemorrhage.

Regulatory Classification

POM

Presentation/Packing

Form

Hemostat cap 500 mg

Packing/Price

2 × 10's

Form

Hemostat inj 250 mg/5 mL

Packing/Price

5 × 1's

Hemostat

tranexamic acid

Manufacturer:

Aristopharma

Distributor:

KTZ